P180 | ACCELERATED INFUSION OF ISATUXIMAB: SINGLE-CENTER REAL-WORLD EVIDENCE SUPPORTING A 30-MINUTE ADMINISTRATION.

Background: Isatuximab (Isa) is an anti-CD38 monoclonal antibody currently approved for relapsed/refractory multiple myeloma (RRMM), in combination with either carfilzomib-dexamethasone (Isa-Kd) after 1 prior line of therapy (LOT) or pomalidomide-dexamethasone (Isa-Pd) after 2 prior LOTs. Infusion-r...

Popoln opis

Bibliografske podrobnosti

Principais autores:	R. Restuccia, K. Mancuso, M. Talarico, M. Puppi, E. Manzato, I. Sacchetti, S. Masci, S. Ghibellini, M. Iezza, P. Tacchetti, L. Pantani, S. Barbato, I. Rizzello, E. Zamagni
Format:	Artigo
Jezik:	Inglês
Izdano:	Ferrata Storti Foundation 2025-09-01
Serija:	Haematologica
Online dostop:	https://haematologica.org/article/view/12377
Oznake:	Označite Brez oznak, prvi označite!